KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Korro Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.91+0.42 (+4.95%)
Close on Oct 19, 2026
- Market cap
- $156.98M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$33.24 (−78.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Korro Bio, Inc. saw revenue fall 62.1% to $2.38M over the twelve months to Jun 30, 2026. Free cash flow was -$68.27M.
Revenue
$2.38M
-62.1% vs. a year earlier
Operating income
-$110.18M
TTM Q2 2026
Free cash flow
-$68.27M
TTM Q2 2026
EPS, diluted
-$10.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $156.98M
- P/E ratio
- –
- Price to sales
- 65.90
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -43.49%
Fundamentals
- Revenue
- $2.38M
- Net income
- -$106.64M
- EPS, diluted
- -$10.00
- Free cash flow
- -$68.27M
- Diluted shares
- 18M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$2.38M-62.1% YoY
Operating income
-$110.18M
Net income
-$106.64M
EPS, diluted
-$10.00
Free cash flow
-$68.27M
Reported periodTrailing twelve months